Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 18, 2021

Versantis reports positive data from decompensated liver cirrhosis study

Swiss pharmaceutical company Versantis has reported positive data from the first-in-human trial of VS-01 in decompensated liver cirrhosis.

Swiss pharmaceutical company Versantis has reported positive data from the first-in-human trial of VS-01 in decompensated liver cirrhosis.

The Phase IB clinical trial tested the safety and tolerability of i.p.-administered VS-01 on top of standard of care in cirrhotic patients with ascites and mild hepatic encephalopathy following single and multiple intraperitoneal administrations.

Overall, the study included 12 patients, of which nine were treated with single ascending dose part (three doses) and three subjects in the multiple dose (daily treatment for four days) part of the study.

The results of the study show that VS-01, a liposomal-based intra-peritoneal fluid, was safe and well tolerated. The study reported no adverse events.

The patients who were administered with multiple doses of VS-01 showed improvements in selected biomarkers and clinical cognitive tests, indicating clinical potentiality of VS-01.

VS-01 therapy aims to reverse Acute-on-Chronic Liver Failure (ACLF) by enhancing the clearance of ammonia and other toxic metabolites from the body.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

A Phase IIA study is planned to assess its efficacy against ACLF.

Goethe University Hospital Frankfurt’s Dr Jonel Trebicka, who led the research, said: “The data show that VS-01 is safe and well tolerated in cirrhotic patients with ascites and covert (mild) hepatic encephalopathy, so very promising.

“We were able to administer VS-01 using standard hospital equipment via the therapeutic paracentesis catheter, which we believe can easily be incorporated into standard of care for patients.

“There are very few treatments available for these patients and VS-01 is complementary to those, so we are excited to continue the trial and hopefully generate the data supporting this ground-breaking clinical approach.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU